Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II trial of imatinib alternating with regorafenib in unresectable metastatic GIST
2015-001298-42Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastrointestinal stromal tumor (GIST) comparing Continuous imatinib with Alternating imatinib and regorafenib (2 arms). Primary endpoint: Objective tumour response. Started Sep 2015; status: completed.
02
Drugs
imatinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2015-001298-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001298-42.